Boston startup Gelesis has picked up $12 million in venture funding, cash that'll support its novel approach to obesity treatment: a pill that disperses expanding particles in the gut to make patients feel full.
George Cotsarelis, a dermatologist at the University of Pennsylvania and a scientific co-founder of a Boston-based biotech, is back in the news with a hair-raising piece on a potential drug breakthrough. And Cotsarelis says he's already started talks with pharma companies interested in the commercial aspects of his work.
Akili Interactive Labs has developed a video game it says can treat ADHD. Now for the tricky part: getting FDA approval.
Humans harbor more than 10,000 microbes that number in the trillions, and sequencing the genomes of the species promises to unlock a wealth of data for biotech entrepreneurs to use in search of new drugs and diagnostics. Now companies have a baseline case for what the sum of microbes in healthy humans should look like.
A Boston and San Francisco-based startup--the year-old Akili Interactive Labs--has formed with the idea of using video games as cognitive therapy, Xconomy reports.
This is a bit of good news for the beleaguered obesity treatment field. Boston-based biotech Gelesis has increased its latest round of financing to $6.2 million and won a $1.3 million grant from the
John LaMattina, Pfizer's former R&D chief, has made the leap into the venture field, joining PureTech Ventures as a senior partner. After putting in 30 years at the drug giant, LaMattina retired